This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Dendreon Announces Data Presentation At The 2012 American Urological Association Annual Meeting

Stocks in this article: DNDN

May 21, 2012–Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 – 23, 2012 in Atlanta, Georgia.

  • “Sipuleucel-T in African Americans: A Subgroup Analysis of Three Phase 3 Trials of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer,” abstract #953. Moderated Poster Session, Prostate Cancer: Advanced III from 10:30 a.m. to 12:30 p.m. ET on Monday, May 21, 2012.
  • “Estimating the Overall Survival Benefit of Sipuleucel-T in the IMPACT Trial Accounting for Crossover Treatment in Control Subjects with Autologous Immunotherapy Generated From Cyropreserved Cells,” abstract #683. Oral Presentation, Prostate Cancer: Advanced 1 Podium from 3:30 to 5:30 p.m. ET on Sunday, May 20, 2012.

“These data continue to support the overall survival benefit of PROVENGE, an important treatment option for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer,” said Mark Frohlich, MD, executive vice president and chief medical officer. “As shown in Phase 3 clinical trials, PROVENGE demonstrated an overall survival benefit and represents an important treatment option for men with advanced prostate cancer.”

Abstract #953: Sipuleucel-T in African Americans: A Subgroup Analysis of Three Phase 3 Trials of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

This exploratory analysis evaluated the survival benefit associated with PROVENGE in the African American men who participated in the three PROVENGE Phase 3 studies, including the IMPACT trial. Among 737 patients with metastatic castrate resistant prostate cancer, 488 were randomized to receive PROVENGE (African American, 33; Caucasian, 437; other races, 18) and 249 were randomized to the control arm (African American, 10; Caucasian, 229; other races, 10). Cox proportional hazards regression analysis was used to assess the treatment effect on overall survival in all randomized patients and the African American subpopulation.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs